Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 2 2

Status

Unknown 1Suspended 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Plasma cell 1Breast 1

Conditions

Peripheral Nervous System Diseases 1Multiple Myeloma 1Breast Neoplasms 1

Interventions

Cisplatin 1041Cyclophosphamide 973Carboplatin 954Radiotherapy 893Bevacizumab 847Gemcitabine 817pembrolizumab 759Paclitaxel 738Docetaxel 734Oxaliplatin 706Capecitabine 649Fluorouracil 564Rituximab 559Nivolumab 506Dexamethasone 487Etoposide 468Doxorubicin 458Irinotecan 442Drug Therapy 402Leucovorin 377Cytarabine 342Cetuximab 340Lenalidomide 326Trastuzumab 323Pemetrexed 315durvalumab 295Filgrastim 287Magnetic Resonance Spectroscopy 278Temozolomide 275Prednisone 274

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × OTHER × G(M1) Ganglioside × Clear all
NCT05751668 2026-06-02

Finding an Effective Dose of GM1 to Reduce or Prevent Neuropathy (Numbness or Weakness) Due to Treatment With Paclitaxel (Phase II)

Alliance for Clinical Trials in Oncology

Phase 2 Suspended
98 enrolled
Breast

Breast Neoplasms

NCT02093910 2014-11-19

Efficacy of Monosialotetrahexosylganglioside in the Prophylactic Treatment of Bortezomib-induced Peripheral Neuropathy

Sun Yat-sen University

Phase 2 Unknown
100 enrolled
Plasma cell

Multiple Myeloma, Peripheral Nervous System Diseases

Data powered by HemOnc (CC BY 4.0) Colophon âš¡